Importantly, clinically approved CFTR modulator therapies restore Nrf2 transcription and activity in CF epithelial cells (Borcherding et al., 2019), and provide an exciting rationale to investigate potential effects of CFTR modulator therapy on the defective functions of the CF endothelium. This evidence concerns the gene CFTR and cystic fibrosis.